Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • ACT Tulsa
  • Contact

News

Sickle cell disease treatment has roots in lab of OMRF’s Dr. Rodger McEver

By sarah | News | 0 comment | 23 December, 2019 | 0

By Scott Meacham There is very big news this month for individuals and families affected by sickle cell disease (SCD). The U.S. Food and Drug Administration (FDA) has approved the first targeted treatment to reduce the frequency of pain crises in individuals living with SCD. This new drug — Adakveo® from Novartis — decreases theRead more

Prescott: A homegrown biotech success story

By sarah | News | 0 comment | 24 November, 2019 | 0

By Stephen Prescott, M.D. When Novartis announced earlier this month that the U.S. Food and Drug Administration had approved the company’s new drug to treat sickle cell anemia, the press release didn’t mention Oklahoma. But it should have. That drug, known as Adakveo, is as Oklahoman as redbuds and scissor-tailed flycatchers. Indeed, but for workRead more

Humble beginnings at Moore gas station launched career of Selexys CEO Scott Rollins

By sarah | News | 0 comment | 11 January, 2017 | 0

Scott Rollins, CEO of Selexys Pharmaceuticals/Oklahoman photo provided by OCAST By Jim Stafford Copyright © 2017, The Oklahoma Publishing Co. Selexys Pharmaceuticals president and CEO Scott Rollins reflected on the lessons learned in the wake of the richest transaction in the history of Oklahoma biosciences — the recent $665 million sale of Selexys to industryRead more

Oklahoma City Finds a Sweet Spot on America’s ‘Silicon Prairie’

By admin | News | 0 comment | 29 November, 2016 | 0

If you are in a decision-making position in an Oklahoma company, is there any reason you wouldn’t want to consider doing business with a startup? You might think that there’s too much risk with a startup. Personally, I like optimism and passion. I favor businesses that stretch, that run lean, and that focus on cashflow. And I like to be part of helping a new business grow. I bet when you think about it, you do too.

Selexys a local success story for entrepreneurship

By admin | News | 0 comment | 29 November, 2016 | 0

If you are in a decision-making position in an Oklahoma company, is there any reason you wouldn’t want to consider doing business with a startup? You might think that there’s too much risk with a startup. Personally, I like optimism and passion. I favor businesses that stretch, that run lean, and that focus on cashflow. And I like to be part of helping a new business grow. I bet when you think about it, you do too.

OKC pharma firm acquired in deal valued up to $665 million

By admin | News | 0 comment | 22 November, 2016 | 0

A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.

i2E portfolio company announces exit

By admin | News | 0 comment | 21 November, 2016 | 0

A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.

i2E-300dpi-Trans-Light
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
PHONE 405/235-2305
Click HERE for printable map with directions.

Tulsa Office

100 S. Cincinnati Ave – 5th Floor, Suite 514
Tulsa, OK 74103
PHONE 918/582-5592
Copyright 2022 i2E, Inc. | All Rights Reserved
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
    • ACT Tulsa
  • e3
  • Concept Fund
  • Portfolio
  • iMCI
  • ACT Tulsa
  • Contact
i2E